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Abstract
Cancer therapy has shown terrific progress leading to important reduction of morbidity and
mortality of several kinds of cancer. The therapeutic management of oncologic patients includes
combinations of drugs, radiation therapy and surgery. Many of these therapies produce adverse
cardiovascular complications which may negatively affect both the quality of life and the prognosis.
For several years the most common noninvasive method of monitoring cardiotoxicity has been
represented by radionuclide ventriculography while other tests as effort EKG and stress myocardial
perfusion imaging may detect ischemic complications, and 24-hour Holter monitoring unmask
suspected arrhythmias. Also biomarkers such as troponine I and T and B-type natriuretic peptide
may be useful for early detection of cardiotoxicity. Today, the widely used non-invasive method of
monitoring cardiotoxicity of cancer therapy is, however, represented by Doppler-
echocardiography which allows to identify the main forms of cardiac complications of cancer
therapy: left ventricular (systolic and diastolic) dysfunction, valve heart disease, pericarditis and
pericardial effusion, carotid artery lesions. Advanced ultrasound tools, as Integrated Backscatter
and Tissue Doppler, but also simple ultrasound detection of "lung comet" on the anterior and
lateral chest can be helpful for early, subclinical diagnosis of cardiac involvement. Serial Doppler
echocardiographic evaluation has to be encouraged in the oncologic patients, before, during and
even late after therapy completion. This is crucial when using anthracyclines, which have early but,
most importantly, late, cumulative cardiac toxicity. The echocardiographic monitoring appears
even indispensable after radiation therapy, whose detrimental effects may appear several years after
the end of irradiation.
Background
In the last decade cancer therapy (CT) has shown a terrific
progress leading to an important reduction of morbidity
and mortality of several kinds of cancer. The therapeutic
management of patients with cancer includes multiple
combinations of drugs, radiation therapy and surgery.
Many of these therapies produce potential adverse cardiac
reactions which can negatively affect the quality of life as
well as the prognosis of oncologic patients.
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In this view, the early detection of cardiotoxicity due to CT
is a critical issue in the clinical setting, in order to interrupt
or modulate appropriately CT and even to sustain ven-
tricular performance by cardiac drugs. The traditional
screening of patients with cancer includes cardiologic
examination, and both EKG and Doppler echocardiogra-
phy at rest. The monitoring of cardiovascular toxicity
might be more accurate by using endomyocardial biopsy
[1] which is, however, invasive and not completely safe.
For several years the most common noninvasive method
of monitoring cardiotoxicity has been represented by radi-
onuclide ventriculography. Other cardiac tests as effort
EKG and stress myocardial perfusion imaging may be
used to detect ischemic myocardial complications, while
24-hour Holter monitoring becomes helpful to unmask
suspected arrhythmias. Also biomarkers such as tropo-
nine I and T [2,3] and B-type natriuretic peptide (BNP and
NT-proBNP) [4,5] may be useful for early diagnosis of car-
diotoxicity.
During time echocardiography is emerged as the choice
test for noninvasive evaluation of cardiac disease due to
cancer therapy. This tool is essential for the evaluation of
left ventricular (LV) systolic and diastolic dysfunction,
pericardial disease, myocardial damage and detailed
information of valvular heart disease. Nevertherless, Dop-
pler echocardiographic examination is routinely planned
only at the beginning of CT in order to document a nor-
mal LV systolic function. Further echocardiographic con-
trols during CT are performed only as a consequence of
the onset of cardiac symptoms and/or signs, in particular
following the administration of recognized cardiotoxic
drugs or the radiation therapy. On these grounds, these
review attempts to demonstrate the clinical need of serial
Doppler echocardiographic evaluation and the potential
impact of advanced ultrasound technologies in patients
undergoing CT.
Cardiac toxicity of chemotherapic agents and 
radiation therapy
Cardiovascular toxicity gives its expression in silent (pre-
clinical) or overt (clinical) events. Pre-clinical toxicity may
be diagnosed by histopathological or biochemical tech-
niques and, even, by detailed imaging techniques. The
grading system proposed by the World Health Organiza-
tion to standardize the report of adverse effects due to CT
does not consider laboratory or modern imaging changes
[6] while the more comprehensive system of the National
Cancer Institute, including all the important clinical and
laboratory changes, should be updated.
Cardiovascular effects associated with CT agents are listed
in Table 1. Anthracyclines (Doxorubicin, Daunorubicin,
Epirubicin, Idarubicin), the best studied anticancer drugs,
widely used for several hematologic and solid tumors,
have a recognized cardiotoxicity, which may be acute and/
or late. Acute cardiotoxicity develops producing non-spe-
cific EKG abnormalities but sometimes also cardiac symp-
toms. Late cardiotoxicity is cumulative (e.g., doses of
doxorubicin > 550 mg/m2), dose-related and may deter-
mine LV systolic dysfunction until congestive heart failure
(CHF). The mechanism underlying this dysfunction is
consequence of a direct myocardial damage induced by
the formation of free radicals [7]. It has been estimated a
very high mortality rate in patients developing anthracy-
cline-related CHF [8] but this rate may be strongly
reduced by early diagnosis and therapy. Alkylators (e.g.,
Busulfan, Cyclophosphamide, Cisplatin, Mytomicin),
commonly used for several solid tumors and lymphomas,
may induce cardiac complications including heart failure,
myocarditis and pericarditis [9]. The mechanism underly-
ing the damage is related to endothelial and cardiomyo-
cyte injury mediated by a toxic metabolism [10]. The total
dose of an individual course, more than the cumulative
dose, appears to be the best predictor of cardiotoxicity of
cyclophosphamide [11]. Cisplatin can determine late car-
diovascular complications (arterial hypertension, myocar-
dial ischemia and infarction), even 10–20 years after the
remission of metastatic cancer [12]. Reported cardiotoxic
effects of Antimetabolities  (5-fluorouacil, capecitabine),
widely used in the treatment of solid tumors, may pro-
duce ischemic syndrome (angina pectoris and myocardial
infarction), arrhythmias and cardiomyopathy [13]. Of
note, the pro-ischemic mechanisms of 5-fluorouracil
include also a very peculiar induction of acute coronary
vasospasm [14]. Antimicrotubule Agents (Paclitaxel, Vinca
Alkaloids), applied to the treatment of several solid
tumors, may induce arrhythmias, thrombosis and myo-
cardial ischemia [15]. Of note, Paclitaxel has been recently
used to coat coronary stents following percutaneous coro-
nary angioplasty. High-dose of Cytokines (Interleukin-2,
Denileukin, Interferon-α), used for treatment of meta-
static renal carcinoma and melanoma, can results in arte-
rial hypotension, vascular leak syndrome, arrhythmias,
cardiomyopathy and vascular thrombosis [16]. The treat-
ment by All-trans Retinoic Acid, a vitamine A derivative
approved for acute promyelocytic leukemia, induces a
syndrome characterized by fever, dyspnoea, arterial hypo-
tension and pericardial/pleural effusion within the first 21
days [17], with depression of LV function in 17% of the
cases [18]. Arsenic Trioxide, used for refractory or relapsed
acute promyelocitic leukemia, provokes QT-interval pro-
longation and arrhythmias in more than 50% of treated
patients but can determine also fluid retention (pleural
and pericardial effusion) [19]. Imatinib Mesylate, a spe-
cific inhibitor of BCR-ABL tyrosine kinase used for chronic
myelogenous leukemia and other malignancies, is associ-
ated with a significant incidence of fluid retention [20].
The most common cardiac adverse effect of therapy by
Etoposide, mainly used for refractory testicular tumors andCardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
Page 3 of 14
(page number not for citation purposes)
small-cell lung carcinoma, is arterial hypotension but
myocardial ischemia may be observed [21]. Monoclonal
Antibodies  (Alemtuzumab, Bevacizumab, Cetuximab,
Rituximab), modernly applied for treatment of some
hematologic malignancies and solid tumors, have toxicity
profiles specific to the blocked receptors but all produces
arterial hypotension [22]. In this category, Trastuzumab,
recombinant IgG1 monoclonal antibody binding selec-
tively to the human epidermal growth factor receptor 2
protein and approved for treatment of breast cancer that
overexpresses HER2, has a recognized incidence of con-
gestive heart failure [23].
The radiation therapy is applied for CT of lymphoma,
breast cancer, thymoma, high and low respiratory ways,
esophageal and gastric lesions. Its damage may involve all
cardiac structures (pericardium, myocardium, valves, cor-
onary arteries) and peripheral vessels, with variable onset
modalities, in relation with dose, irradiation modality,
contemporary administration of chemotherapic agents
(in particular doxorubicin) and baseline patient's clinical
condition [24]. Cardiovascular complications of radiation
therapy may be acute and chronic. Some of these are true
medical and/or surgery emergencies (cardiac tamponade,
acute myocardial infarction, cardiac arrest). Others,
mainly due to the progression of coronary atherosclerosis,
remain silent for several years and produce during time
severe coronary heart disease, even in absence of concom-
itant cardiovascular risk factors [25,26]. These vascular
lesions correspond to intima hyperplasia and lumen wall
collagen deposition, develop throughout a period of
about 82 months and involve also carotid arteries, induc-
ing stenosis particularly frequent at the level of bifurca-
tion [27]. Of interest, heart valves are affected by collagen
deposition due to radiation therapy and valvular stenosis
or regurgitation may be severe, in particular at the level of
mitral and aortic valves [25,27]. Pericardial involvement
is, however, the most frequent anatomic consequence of
radiation therapy. The right ventricle is more often and
more extensively involved. The interval occurring between
the radiation therapy and symptom onset is variable,
ranging from 2 to 145 months and constrictive pericardi-
tis, silent for several years, produces hemodynamic altera-
tions which become clinically overt even long time after
the cessation of x-ray exposition [28,29]. Importantly, the
prevalence of all the abnormalities induced by the radia-
tion therapy increased dramatically over time, making a
strong argument for screening because they remained
clinically unrecognized. In the past 30 years, radiation
therapy has been deeply modified to reduce the total radi-
ation dose administered and to better shield the cardiac
structures. The prevalence of these cardiac abnormalities
will, thus, realistically decrease in the patients treated
more recently.
Table 2 shows schematically the different cardiovascular
cellular and extracellular targets of CT [30-33]. It is worthy
of note that some of these detrimental effects are actually
used even beneficially in medicalized intracoronary stents
to prevent restenosis after percutaneous coronary angi-
oplasty. The cardiotoxicity of CT depends, however, on
multiple factors which include the drug itself or radiation
therapy but also the patient's individual characteristics.
Dose of the administered drug during each session, cumu-
lative dose, schedule of delivery, route of administration,
combination with other drugs and with irradiation,
sequence of administration of multiple medications
should be taken carefully into account. Patient-related fac-
tors include age, pre-existing cardiovascular risk factors
and previous cardiac disease, metabolic abnormalities
and hypersensitivity to the given drug. In any case, CT-
related cardiotoxicity may be acute (in particular immedi-
ately after a single dose of a course of anthracycline ther-
apy), late, i.e. developing at long-term over time after
completion of therapy, and very late, that is even 144
months (= 12 years) after the completion of radiation
therapy or of multiple chemotherapies (Figure 1). This
aspect is crucial to understand that the duration of cardi-
ologic monitoring of patients undergoing CT needs to be
very long and accurate.
EKG and cardiotoxicity of CT
EKG represents the traditional support and completion to
the clinical examination also for patients undergoing CT
but EKG abnormalities are often non specific in this clin-
ical setting. This is particularly true for anthracycline-
Table 1: Adverse cardiovascular effects of cancer therapy
Adverse cardiac effect Therapy
Heart failure Anthracycline, Mitomycin, Cyclophosphamide, Cisplatin, Trastuzumab, Alemtizumab
Pericardial/Pleural effusion Cyclophosphamide, Cytarabine, Imatinib, Thalidomide, Trans-retinoic acid, Busulfan, Radiation therapy
Myocardial ischemia Cisplatin, Vinca Alkaloids, Capecitabine, Interleukin-2 Bevacizumab, 5-Fluotouracil, Radiation therapy
Arterial hypertension Cisplatin, Bevacizumab, Interferon-α
Arterial hypotension Etoposide, Talidomide, Paclitaxel, Alemtuzumab, Cetuximab, Rituximab, Transretinoic Acid, Interleukin-2, Interferon-α
Myocarditis Busulfan, Cyclophoshamide, Radiation Therapy
Bradycardia Thalidomide, Paclitaxel
QT prolongation Arsenic Troxide
Thromboembolis Bevacizumab, PaclitaxelCardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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induced acute toxicity, where non-specific ST-segment
and T-wave changes, decreased QRS voltage and QT-inter-
val prolongation have been described. Chronic anthracy-
cline cardiotoxicity (even many years after the completion
of therapy) manifests often as life-threatening arrhyth-
mias [34]. 5-Fluorouracil has been demonstrated to be
associated with EKG signs of myocardial ischemia while
less frequent alterations include arrhythmias [35]. High
dose of cyclophosphamide may cause malignant arrhyth-
mias inducing sometimes fatal outcomes [36]. The most
severe EKG alterations of interferon-α and interleukin-2
correspond to supra-ventricular and ventricular arrhyth-
mias [37]. Effort EKG test may be useful to unmask coro-
nary artery spasm induced by capecitabine, showing ST-
segment elevation accompanied by angina [38]. Twenty-
four-hour Holter monitoring and analysis of QT-interval
Table 2: The main cardiovascular cellular and extracellular targets of CT
Target Damage Kind of CT
Endothelial cells Anthracyclines, Cyclophosphamide, 5-fluorouracil (TNF-α induced apoptosis), Monoclonal antibodies, Radiation therapy
Cardiomyocytes Anthracyclines (atrophy and apoptosis), Cyclophosphamide, Cisplatin, 5-fluorouracil, Monoclonal antibodies (mitochondrial 
apoptosis), Radiation therapy
Smooth muscle cells Anthracyclines Cytarabine, Cisplatin, 5-fluorouracil, Cytokines, Arsenic trioxide, Radiation therapy
Extracellular matrix Anthracyclines, Cisplatin, 5-fluorouracil, Radiation therapy
Schematic view of the time course of CT-related cardiotoxicity Figure 1
Schematic view of the time course of CT-related cardiotoxicity. CT = cancer therapy.Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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dispersion may be important tools in patients undergoing
CT, to detect number and severity of arrhythmias [39].
Increased QT-interval dispersion has been recently found
to be a predictor of acute heart failure after therapy by
cyclophosphamide [40] and to persist even in late survi-
vors of childhood anthracycline treatment [41]. In rela-
tion with symptoms and signs of congestive heart failure,
often developing during CT, it is, however, clear how EKG
represents a limited tool for serial cardiologic assessment
and early diagnosis of cardiac adverse effects and compli-
cations due to CT.
Doppler-echo and cardiovascular toxicity of CT
Today, the widely used non-invasive method of monitor-
ing cardiotoxicity of CT is certainly represented by Dop-
pler echocardiography which allows to identify the main
forms of cardiac involvement in cancer patient: LV (systo-
lic and diastolic) dysfunction, valve heart disease, pericar-
ditis and pericardial effusion, and carotid artery lesions.
The form of CT-related cardiac involvement of the greatest
interest and concern among oncologists and cardiologists
is LV dysfunction which may progress until overt conges-
tive heart failure [42]. LV endocardial fractional shorten-
ing and ejection fraction (EF) are the most common
echocardiographic indexes of LV systolic function, used to
quantify the degree of LV systolic dysfunction also in
oncologic patients. Figure 2 shows the acute reduction of
EF in a patient treated by an association of chemotherapic
agents because of a granulocytic sarcoma. EF is, however,
not very sensitive for the early diagnosis of preclinical
heart disease. It is now recognized that the impairment of
Doppler-derived diastolic indexes represents an early sign
of LV dysfunction also in patients undergoing CT [43].
The diagnostic role of Doppler echocardiography for diag-
nosing LV dysfunction has been analyzed during and after
anthracycline therapy. By using these drugs rare cases of
acute and subacute cardiotoxicity resulting in acute heart
failure were reported. A study performed to investigate
possible acute effects in 88 patients with Hodgkin's lym-
phoma (average anthracycline dose = 174 mg/m2 + aver-
age mediastinum irradiation dose = 21 Gy = 21 Sv =
210.000 chest x-rays) did not show significant changes of
M-mode derived LV end-diastolic diameter, end-systolic
diameter and EF but identified regional wall motion
abnormalities (hypokinesis) by 2D assessment [44]. The
chronic cardiotoxicity often induces cumulative dose-
related LV dysfunction and failure, which may be early
detected by monitoring again Doppler diastolic indexes
more than EF [45]. Early peak flow velocity to atrial peak
flow velocity (E/A) ratio, deceleration time and isovolu-
mic relaxation time were all impaired (grade I of diastolic
dysfunction) in more than 50% of patients treated by
anthracyclines, when EF was still normal [46]. Figure 3
depicts the shift of a baseline normal standard Doppler
pattern of LV diastolic function to a pattern of LV abnor-
mal relaxation (grade I of diastolic dysfunction) after
DNR protocol (= daunorubicine + etoposide + cytarabine)
in a woman affected by acute myeloid leukemia. The alter-
ation of LV diastolic function occurs particularly in child-
hood, much more sensitive to the late cardiotoxicity of
these chemotherapic agents [47,48]. In this context, myo-
cardial performance index (= isovolumic contraction time
+ isovolumic relaxation time/ejection time), accurate
marker of global LV function, may be particularly useful
since it appeared significantly altered in 35 doxorubicin-
treated children compared with that in 32 age-matched
control subjects (0.42 ± 0.07 vs. 0.34 ± 0.06, p < 0.001)
[49]. Serial echocardiograms performed in 101 patients
with acute lymphoblastic leukemia and 83 survivors of
Wilms tumor after a mean interval > 6 years since last
anthracycline dose demonstrated that the most important
predictor of worsening cardiac performance in childhood
is the cumulative dose (> 240 mg/m2) [50]. The echocar-
diographic evaluation of cardiotoxicity due to drugs other
than anthracyclines is less described. Echo monitoring
appeared very useful to detect significant increase of both
LV end-diastolic and end-systolic diameters/volumes,
without decrease of fractional shortening, and reduction
of transmitral E/A ratio in breast cancer patients undergo-
ing high-dose (7 g/m2) cyclophoshamide [51]. Advanced
breast cancer patients receiving epirubicin 90 mg/m2 +
paclitaxel 200 mg/m2 showed reduction of two-dimen-
sional EF from baseline median value of 60% to median
value of 50% after 8 courses [52]. Hypokinesis and
decreased EF were observed after high-dose bolus of inter-
leukin-2 and interferon-α in 16 patients treated for meta-
static melanoma [53]. Of interest, while the imatinib
mesylate administration may increase cardiac morbidity
in advanced chronic myelogenous leukaemia treated by
successive allogenic stem cell transplantation with busul-
phan/cyclophoshamide conditioning [54], the same drug
appears able to induce a rapid, echocardiographically
detected, reversion of Loeffler's endocarditis in early stage
of clonal hypereosinophilic syndrome [55]. Echocardiog-
raphy allowed also to unmask LV dysfunction in 39% of
41 patients, 5 years or more after receiving cardiac radia-
tion for Hodgkin's disease or seminoma in remission
[56]. The effect of radiation therapy (mediastinal irradia-
tion for treatment of Hodgkin disease) on LV diastolic
function was recently described by Doppler assessment:
among the recruited 294 patients receiving at least 35 Gy
(= 350.000 chest x-rays) to the mediastinum [57]. Worthy
of note, patients with LV diastolic dysfunction had worse
event-free survival than patients with normal function
(hazard ratio 1.66, 95% CI 1.06–2.4) in a 3.2 year follow-
up [57]. Data collected on the same population show that,
compared with the Framingham Heart Study population,
mildly reduced endocardial fractional shortening (<30%)
was more common (36% vs. 3%), and age- and gender-Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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adjusted LV mass was lower (90 ± 27 g/m vs. 117 g/m) in
irradiated patients [58].
Also the documentation of valvular heart disease, devel-
oping as chronic CT of chemotherapic agents, concerns
mainly anthracycline treatment. In a population of 305
patients (median age = 14 years), treated with a cumula-
tive dose ranging 140–450 mg/m2 for childhood malig-
nancy, color flow Doppler detection of mitral
regurgitation was evident in 34 patients (11.6%) com-
pared with only 1.8% of a normal population of similar
age (p < 0.0001) [59]. Since increased risk of left sided val-
vular regurgitation, in particular aortic regurgitation, was
related to high-dose mediastinal radiation in 129 patients
with Hodgkin's disease [60], echocardiographic screening
is highly recommended in this clinical setting. This was
confirmed in a retrospective study where, among patients
treated with radiation therapy for Hodgkin lymphoma,
there was statistically higher than expected rate of valve
surgery and coronary revascularization procedures over
the next 10 to 20 years [61] After a mean follow-up of 9.5
years the morbidity of valvular heart disease was about
2.8–2.9% in women who had undergone adjuvant radio-
therapy for breast cancer [62]. The echocardiographic
analysis of Heidenriech et al [58] observed that 60% of
patients who had experienced irradiation (for Hodgkin's
disease) more than 20 years earlier presented mild aortic
regurgitation while 15% had moderate to severe aortic
regurgitation. Despite the high prevalence of aortic valve
disease in these patients, aortic regurgitation was rarely
identified by physical examination. The echocardio-
graphic features of radiation-associated valvular disease
were described by Hering et al, who reported evidence of
combined calcific transformation of the mitral valve, aor-
tic valve and the aortic-mitral aponeurosis, i.e., the junc-
tion between the base of the anterior mitral leaflet and the
aortic root [63].
Malignant pericardial disease is a serious but not uncom-
mon problem seen in patients with cancer, usually due to
metastatic spread of the underlying malignancy. Pericar-
ditis and pericardial effusion can be also due to chemo-
therapy and, above all, to radiation therapy [64]. The
patient may have a mild, subtle presentation, as often
seen in the early stage of pericardial effusion, or may expe-
rience dramatic hemodynamic compromise, as occurring
with cardiac tamponade and constrictive pericarditis. In
all the cases, early diagnosis by echocardiography is fun-
damental. Observations of pericarditis and/or pericardial
effusion induced by both acute and chronic anthracycline
therapy were reported [44,65]. Radiation therapy is, how-
ever, the main cause of pericarditis and pericardial effu-
sion, in an overall 30% incidence of clinically detectable
heart injury after thoracic irradiation [66,67]. Acute peri-
carditis may occur early in the course of treatment, but
constrictive or effusive pericarditis develop even months
to years after therapy completion [67]. Acute and chronic
pericarditis [68] and late appearance of chronic pericar-
dial disease [69,70] after mediastinal radiation for Hodg-
kin lymphoma were reported in echocardiographic
studies. In view of these findings, the size of the effusion
has to be graded for appropriate management and com-
parison of repeated, serial examinations. The usual
echocardiographic grading measures the echo free space
in diastole [71] while the classification of Horowitz et al
[72] takes into account the epicardium-pericardium sepa-
Acute LV systolic dysfunction in a 50-year old female patient affected by granulocytic sarcoma during CT by daunorubicine (50  mg/m2), cytarabine (30 mg/m2), etoposide 50 mg/m2 Figure 2
Acute LV systolic dysfunction in a 50-year old female patient affected by granulocytic sarcoma during CT by daunorubicine (50 
mg/m2), cytarabine (30 mg/m2), etoposide 50 mg/m2. LV end-diastolic diameter (left panel) is 48.9 mm and LV end-systolic 
diameter (right panel) is 41.7 mm. Thus, endocardial fractional shortening is 14.7 % and EF = 37.9 %. EF = Ejection fraction, LV 
= Left ventricular.Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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ration in the different phases of the cardiac cycle (type A =
no effusion, type B = systolic epicardium-pericardium sep-
aration corresponding to 3–16 ml, type C1 = systolic and
diastolic separation corresponding to >16 ml, type C2 =
systolic and diastolic separation with attenuated pericar-
dial motion, type D = pronounced separation, with large
echo-free space, type E = pericardial thickening [> 4 mm]).
In addition, Doppler-echo signs of cardiac tamponade
(exaggerated inspiratory variation of the two ventricles,
right atrial and/or right ventricular collapse, left atrial
and/or left ventricular collapse, inferior cava plethora,
abnormal increased respiratory variation in transvalvular
blood flow velocities) should be promptly diagnosed
[71]. The search of pericardial effusion and thickening
should be performed by multiple views (including sub-
costal view), in order to explore the entire pericardial sta-
tus. Figure 4 shows a mild pericardial effusion in a woman
affected by non Hodgkin's lymphoma and treated by a
CHOP association and previous mediastinal radiation
therapy.
Asymptomatic carotid arterial disease occurs frequently
in young patients following head and neck radiation ther-
apy. Doppler-echo scan of carotid arteries allowed to
Doppler transmitral inflow pattern in a 58-year old female patient with acute myeloid leukemia before treatment (upper panel)  and after DNR (= daunorubicine) 50 mg/m2, VP16 (= etoposide) 50 mg/m2, ARA-C (= cytarabine) 30 mg/m2 (lower panel) Figure 3
Doppler transmitral inflow pattern in a 58-year old female patient with acute myeloid leukemia before treatment (upper panel) 
and after DNR (= daunorubicine) 50 mg/m2, VP16 (= etoposide) 50 mg/m2, ARA-C (= cytarabine) 30 mg/m2 (lower panel). 
Transmitral pattern, normal before treatment (transmitral E/A ratio = 1.12, deceleration time = 172 ms), shifts to pattern of 
LV abnormal relaxation, corresponding to grade I of LV diastolic dysfunction (E/A ratio = 0.70, deceleration time = 230 ms) 
after CT.Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
Page 8 of 14
(page number not for citation purposes)
detect increased intima-media thickness in 24% of 42 sur-
vivors of Hodgkin lymphoma who had undergone radia-
tion therapy more than 5 years earlier and one patient had
greater than 70% stenosis of both common carotid arter-
ies [73]. This findings were recently confirmed in 12/21
patients, irradiated for Hodgkin disease, non Hodgkin
lymphoma and seminoma, who developed atheroscle-
rotic carotid vascular disease [74]. In this view, the obser-
vation that survivors of childhood Hodgkin disease
undergoing mantle irradiation are at increased risk of
stroke (RR = 5.62, 95% CI = 2.59 to 12.25, p < 0.0001) is
not unexpected [75].
All together, these findings highlight the ultrasound abil-
ity to unmask cardiovascular abnormalities in sympto-
matic as well as in asymptomatic patients undergoing CT.
It emerges also by our retrospective experience including
148 echocardiographic observations from patients refer-
Detection of posterior pericardial effusion in a 28-year old female patient affected by non Hodgkin's lymphoma and treated by  CHOP (Cyclophosphamide 750 mg/m 2 + Adriamycin 50 mg/m 2 + Vincristine 2 mg + Prednisone 100 mg) and previous medi- astinal radiation therapy Figure 4
Detection of posterior pericardial effusion in a 28-year old female patient affected by non Hodgkin's lymphoma and treated by 
CHOP (Cyclophosphamide 750 mg/m 2 + Adriamycin 50 mg/m 2 + Vincristine 2 mg + Prednisone 100 mg) and previous medi-
astinal radiation therapy. The usual grading of pericardial effusion takes into account the diastolic separation between epicar-
dium and pericardium: 1. small = < 10 mm corresponding to 300 ml, 2. moderate = 10–20 mm corresponding to 500 ml, 3. 
severe = > 20 mm corresponding to > 700 ml). In this patient the diastolic separation is < 10 mm (both in long and in short-
axis vies), indicating mild pericardial effusion. Upper panel; visualization of diastolic pericardial effusion in parasternal long-axis 
(left panel) and short-axis view (right panel). Lower panel: visualization of systolic pericardial effusion in parasternal long-axis 
(left panel) and short-axis view (right panel).Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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ring to our echo-lab for hematologic malignancies and
showing CT-related abnormalities of LV function, pericar-
dium and heart valves [76].
Stress echocardiography and detection of 
cardiotoxicity
Dobutamine stress echocardiography was tested in several
studies to detect subclinical abnormalities of LV function
induced by anthracycline cardiotoxicity [77-81] but the
findings of these studies appear insufficient or controver-
sial. In two reports [77,78] low-dose dobutamine, per-
formed to oncologic patients before, during and after 6
months following chemotherapy, was able to unmask a
reduced contractile reserve only in patients who had
already depressed LV systolic function and standard Dop-
pler pattern of LV abnormal relaxation at rest. In the expe-
rience of Lanzarini et al [80], young oncologic patients,
who had undergone high-dose anthracycline therapy
(>400 mg/m2) and had normal LV structure and function
at rest, did not show significant modifications during a
modified/accelerated dobutamine protocol (achievement
of the maximal dose of 15 mg/Kg/min in a short time).
On the other hand, Hamada et al, by using high-dose dob-
utamine (30 mg/Kg/min), evidenced alteration of poste-
rior wall thickness, fractional shortening and transmitral
E/A ratio in patients treated by high-dose anthracycline
and free of cardiologic symptoms (81).
Stress echocardiography, an optimal tool to unmask coro-
nary artery disease in the general population, remains
important also in patients treated by some chemotherapic
agents (e.g., capecitabine) and in particular by radiation
therapy, which is able to provoke accelerated coronary
atherosclerosis. Experiences dealing with the use of stress
echocardiography in this clinical setting are, however,
lacking until now.
Advanced ultrasound tools for early detection of 
cardiotoxicity
Some high-tech ultrasound tools as Integrated Backscatter
(IBS) and Tissue Doppler have been used with the aim to
identify subclinical alterations of both LV structure and
function in patients treated by CT.
Analysis of acoustic intensity of the backscattered signal
consists of the omni-directional scattering energy redi-
rected back to the transducer, with different intensity
according to the density of the reflecting tissue [82]. IBS,
which reliably identifies in vivo variations in the regional
extent of myocardial fibrosis [83,84], was successfully
used in 28 oncologic patients under HDLV5FU chemo-
therapy. In these patients the magnitude of both anterior
and posterior cardiac IBS values significantly decreased at
48th  hour of treatment compared with 0th  hour but
returned near the baseline values at day 15 (p = 0.003),
suggesting a reversible, acute 5-fluorouracile toxicity [85].
In addition, in relation with the recognized diastolic-to-
systolic variation of IBS signal [86], cyclic-variation-IBS of
posterior wall appeared decreased in 32 patients with non
Hodgkin's lymphoma after 300 mg/m2 of doxorubicin,
this decrease being higher in patients treated by moderate
and high-dose than in those undergoing low dose [87].
IBS requires time-expensive, off-line analysis and normal-
ization for the pericardial interface, inducing possible arti-
facts. In contrast, pulsed Tissue Doppler may be easily
performed during a standard Doppler echocardiographic
examination by using a high-pass filter and placing a sam-
ple volume on a given region of interest [88]. It has been
successfully applied in several clinical setting and appears
reliable to provide quantitative information on myocar-
dial diastolic relaxation and systolic performance [88].
Tissue Doppler of LV lateral mitral annulus has a recog-
nized prognostic role [89] and, in combination with
standard Doppler mitral inflow, provides accurate infor-
mation about the degree of LV filling pressure [90]. Early
changes in LV myocardial function of oncologic patients
were found by pulsed Tissue Doppler of multiples LV sites
(mitral annulus, basal LV lateral and basal LV posterior
wall) early after (1–3 months) and, more accentuated, at
the late control (3.5 ± 0.6 years) after the completion of
doxorubicin therapy (cumulative dose = 211 ± 82 g/m2).
In these patients also myocardial systolic dysfunction was
evident, in presence of normal EF [91,92]. Similar find-
ings were observed also in survivors of childhood cancer
treated with anthracyclines [93], while no experience is
available about the use of Tissue Doppler in patients
treated by other chemotherapic agents or radiation ther-
apy. Figure 5 depicts standard Doppler mitral inflow pat-
tern and Tissue Doppler of septal and lateral mitral
annulus in a in a 38-year male patient affected by acute
pro-myelocitic leukemia undergoing idarubicine and
trans-retinoic acid: transmitral E/A ratio is normal (>1)
but the ratio between transmitral E and the average value
of Tissue Doppler derived Em (Septal Em + Lateral Em/2)
is = 10.4 (normal values < 8), indicating an initial increase
of LV filling pressure.
An useful tool to identify early markers of pulmonary con-
gestion following to heart failure could be represented by
the ultrasound "lung comet", an echocardiographic sign
detectable with the ultrasound scan of anterior and lateral
chest (from the second to the fifth intercostal space). It is
visualized as multiple comet-tails fanning out from the
lung surface [94]. It originates from water-thickened or
fibrotic interlobular septa and allows a bedside distinc-
tion between pulmonary edema and obstructive lung dis-
ease [95,96]. "Lung comet" can be particularly appealing
for identifying and quantifying extravascular lung water, a
hinge parameter in the serial evaluation of the cardiologicCardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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patient with heart failure [97]. Of interest, this sign is
detectable before the onset of pulmonary rales by lung
auscultation, does not need sophisticated technology and
may be performed at bedside, even with hand-held
echocardiographic machines of low cost and limited
tools. Specific applications of ultrasound "lung comet" for
CT monitoring has not yet reported but in our clinical
practice it can be visualized particularly in oncologic
patients who experienced radiation therapy (Figure 6). In
these cases it might be considered a sign of alveolar-capil-
lary membrane distress (ARDS-like syndrome), already
demonstrated by other imaging techniques and due to
acute, deterministic, combined radiation and chemo-ther-
apy [98,99].
Conclusion
A large amount of data demonstrate how Doppler
echocardiography represents the election tool not only for
baseline cardiologic screening but also for follow-up of
the oncologic patients during and after the completion of
CT. In relation with its low cost, feasibility and reliability
to diagnose LV systolic and diastolic dysfunction, regional
Sample of the combination of standard Doppler mitral inflow and Tissue Doppler of septal and lateral mitral annulus in a 38- year male patient affected by acute promyelocytic leukemia undergoing CT by idarubicine (12 mg/m2) + trans-retinoic acid (45  mg/m2) Figure 5
Sample of the combination of standard Doppler mitral inflow and Tissue Doppler of septal and lateral mitral annulus in a 38-
year male patient affected by acute promyelocytic leukemia undergoing CT by idarubicine (12 mg/m2) + trans-retinoic acid (45 
mg/m2). In the upper panel transmitral E/A ratio is > 1 (E peak velocity = 0.78 m/s); In the lower panels Tissue Doppler derived 
Em peak velocity is 0.07 m/s (left panel) and 0.08 m/s (right panel) respectively, determining an average Em = 0.075 m/s. Thus, 
E/Em ratio is = 10.4, indicating an initial increase of LV filling pressure (normal values of E/Em ratio < 8, see Ref # 90). E = trans-
mitral early diastolic peak velocity, Em = Tissue Doppler derived myocardial early diastolic peak velocity.Cardiovascular Ultrasound 2007, 5:4 http://www.cardiovascularultrasound.com/content/5/1/4
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wall motion abnormalities, valve disease, pericardial
abnormalities and carotid lesions, the ultrasound exami-
nation appears very useful to identify and monitor CT-
related cardiac conditions over time. This is really crucial
when using some chemotherapic agents as anthracyclines,
which have early but, most importantly, late and very late,
cumulative cardiac toxicity. The late cardiac toxicity may
be stopped or at least blunted by a prompt pharmacolog-
ical intervention. The echocardiographic monitoring
appears even indispensable after radiation therapy, whose
detrimental effects may appear several years after the end
of irradiation. Under these circumstances and given the
high likelihood of diagnosing significant cardiovascular
pathologies, an ultrasound screening 10 years after irradi-
ation is recommendable also in patients who remain
asymptomatic and should be extended to the exploration
of carotid arteries in patients undergoing mantle irradia-
tion. In all the cases the performance of Doppler-echo
examination should be very flexible, prone to the assess-
ment of multiple parameters of LV systolic and diastolic
function (including Tissue Doppler of LV mitral annulus),
to the detection and grading of valvular heart disease, to
the visualization of overall pericardium by multiple views
and even to the measure of carotid intima-media thick-
ness (Table 3). Bio-humoral markers of cardiac function
(BNP and NT-proBNP) could provide further support dur-
ing the follow-up and indicate the right timing for repeti-
tion of Doppler echocardiographic examination in
subgroups at risk for heart failure (91). This will be useful
to anticipate treatment and decide the most appropriate
pharmacological therapy for congestive heart failure at its
early onset.
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